MedTrace Logo

First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease

NCT01247428 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-12-19

Study results available
· View outcomes & findings →

Summary

The DESSOLVE I clinical trial is to assess the safety and performance of the sirolimus-eluting MiStent SES.

Conditions

Interventions

DEVICE

MiStent SES

The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).

Sponsors & Collaborators

  • Micell Technologies

    lead INDUSTRY

Principal Investigators

  • William Wijns, MD · Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis Aalst (OLV Hospital)

  • John Ormiston, MD · Mercy Angiography Unit

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-09-30
Completion
2016-03-31

Countries

  • Australia
  • Belgium
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01247428 on ClinicalTrials.gov